Show simple item record

dc.contributor.authorCox, David Benjamin Turitz
dc.contributor.authorPlatt, Randall Jeffrey
dc.contributor.authorZhang, Feng
dc.date.accessioned2016-07-20T19:54:51Z
dc.date.available2016-07-20T19:54:51Z
dc.date.issued2015-02
dc.identifier.issn1078-8956
dc.identifier.issn1546-170X
dc.identifier.urihttp://hdl.handle.net/1721.1/103783
dc.descriptionAvailable in PMC 2015 July 06en_US
dc.description.abstractRecent advances in the development of genome editing technologies based on programmable nucleases have substantially improved our ability to make precise changes in the genomes of eukaryotic cells. Genome editing is already broadening our ability to elucidate the contribution of genetics to disease by facilitating the creation of more accurate cellular and animal models of pathological processes. A particularly tantalizing application of programmable nucleases is the potential to directly correct genetic mutations in affected tissues and cells to treat diseases that are refractory to traditional therapies. Here we discuss current progress toward developing programmable nuclease–based therapies as well as future prospects and challenges.en_US
dc.description.sponsorshipRobert Metcalfeen_US
dc.description.sponsorshipSimons Foundationen_US
dc.description.sponsorshipMerkin Family Foundation for Stem Cell Researchen_US
dc.description.sponsorshipNational Science Foundation (U.S.) (NSF Waterman Award)en_US
dc.description.sponsorshipNational Science Foundation (U.S.) (NSF Graduate Research Fellowship, grant number 1122374)en_US
dc.description.sponsorshipNational Institute of General Medical Sciences (U.S.) (Award number T32GM007753)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) ((NIH) Director’s Pioneer Award (DP1-MH100706))en_US
dc.description.sponsorshipW. M. Keck Foundationen_US
dc.description.sponsorshipNational Institute of Neurological Disorders and Stroke (U.S.) (NIH Transformative R01 grant (R01-NS 07312401))en_US
dc.description.sponsorshipDamon Runyon Cancer Research Foundationen_US
dc.description.sponsorshipSearle Scholars Programen_US
dc.description.sponsorshipEsther A. & Joseph Klingenstein Fund, Inc.en_US
dc.description.sponsorshipVallee Foundationen_US
dc.language.isoen_US
dc.publisherSpringer Natureen_US
dc.relation.isversionofhttp://dx.doi.org/10.1038/nm.3793en_US
dc.rightsCreative Commons Attribution-Noncommercial-Share Alikeen_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/en_US
dc.sourcePMCen_US
dc.titleTherapeutic genome editing: prospects and challengesen_US
dc.typeArticleen_US
dc.identifier.citationCox, David Benjamin Turitz, Randall Jeffrey Platt, and Feng Zhang. "Therapeutic genome editing: prospects and challenges." Nature Medicine 21:2 (February 2015), pp.121-131.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biological Engineeringen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Biologyen_US
dc.contributor.departmentMassachusetts Institute of Technology. Department of Brain and Cognitive Sciencesen_US
dc.contributor.departmentMcGovern Institute for Brain Research at MITen_US
dc.contributor.mitauthorCox, David Benjamin Turitzen_US
dc.contributor.mitauthorPlatt, Randall Jeffreyen_US
dc.contributor.mitauthorZhang, Fengen_US
dc.relation.journalNature Medicineen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsCox, David Benjamin Turitz; Platt, Randall Jeffrey; Zhang, Fengen_US
dspace.embargo.termsNen_US
dc.identifier.orcidhttps://orcid.org/0000-0003-2782-2509
dc.identifier.orcidhttps://orcid.org/0000-0001-7626-4254
mit.licenseOPEN_ACCESS_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record